MARGOLIS, JEFFREYM.D. NPI 1871577544 Clinician
Hematology-Oncology · MADISON HEIGHTS, MI
- MICHIGAN HEALTHCARE PROFESSIONALS PC — FARMINGTON HILLS, MI
Group affiliation since 2019
The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.
Year: 2024 · 2023 · 2022 locked column · 2021 locked column · 2020 locked column
Provider overview · all codes · CY2024
The full analytics for this provider
PremiumThe billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.
- Payment, service & beneficiary totals — the disclosed scale, all codes
- Practice profile — focus & reach — top codes by share of services
- Office vs. facility setting mix — place-of-service code split
- Volume over five years — discrete yearly counts, no rate
- Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
- Peer positioning — code breadth — how many codes billed, vs peers
Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.
Notify me at launch → Or see a live example profile →Procedures billed to Medicare Part B (2024)
Medicare Part B FFS · CY2024 · as published by CMS| Code | Description | Services locked column | Beneficiary-episodes locked column | Avg charge locked column | Avg Medicare payment locked column |
|---|---|---|---|---|---|
| J1439 | Injection, ferric carboxymaltose, 1 mg | premium | premium | premium | premium |
| J9263 | Injection, oxaliplatin, 0.5 mg | premium | premium | premium | premium |
| J1453 | Injection, fosaprepitant, 1 mg | premium | premium | premium | premium |
| J9271 | Injection, pembrolizumab, 1 mg | premium | premium | premium | premium |
| J9299 | Injection, nivolumab, 1 mg | premium | premium | premium | premium |
| J0897 | Injection, denosumab, 1 mg | premium | premium | premium | premium |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | premium | premium | premium | premium |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | premium | premium | premium | premium |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | premium | premium | premium | premium |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | premium | premium | premium | premium |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | premium | premium | premium | premium |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | premium | premium | premium | premium |
| J2469 | Injection, palonosetron hcl, 25 mcg | premium | premium | premium | premium |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | premium | premium | premium | premium |
| 80047 | Blood test, basic group of blood chemicals (calcium, ionized) | premium | premium | premium | premium |
| J0640 | Injection, leucovorin calcium, per 50 mg | premium | premium | premium | premium |
| 99213 | Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | premium | premium | premium | premium |
| J9190 | Injection, fluorouracil, 500 mg | premium | premium | premium | premium |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | premium | premium | premium | premium |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | premium | premium | premium | premium |
| 99214 | Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | premium | premium | premium | premium |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | premium | premium | premium | premium |
| J3489 | Injection, zoledronic acid, 1 mg | premium | premium | premium | premium |
| 96372 | Injection of drug or substance under skin or into muscle | premium | premium | premium | premium |
| 96375 | Injection of additional new drug or substance into vein | premium | premium | premium | premium |
| J9045 | Injection, carboplatin, 50 mg | premium | premium | premium | premium |
| J3475 | Injection, magnesium sulfate, per 500 mg | premium | premium | premium | premium |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | premium | premium | premium | premium |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | premium | premium | premium | premium |
| J9196 | Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg | premium | premium | premium | premium |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | premium | premium | premium | premium |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | premium | premium | premium | premium |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | premium | premium | premium | premium |
| 96415 | Administration of chemotherapy into vein, each additional hour | premium | premium | premium | premium |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | premium | premium | premium | premium |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | premium | premium | premium | premium |
| J3490 | Unclassified drugs | premium | premium | premium | premium |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | premium | premium | premium | premium |
| 96411 | Administration of additional new drug or substance into vein using push technique | premium | premium | premium | premium |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | premium | premium | premium | premium |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | premium | premium | premium | premium |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | premium | premium | premium | premium |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | premium | premium | premium | premium |
| 99212 | Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more | premium | premium | premium | premium |
| J7030 | Infusion, normal saline solution , 1000 cc | premium | premium | premium | premium |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | premium | premium | premium | premium |
| 96374 | Injection of drug or substance into vein | premium | premium | premium | premium |
| 99215 | Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more | premium | premium | premium | premium |
| 96361 | Infusion into a vein for hydration, each additional hour | premium | premium | premium | premium |
| 99205 | New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more | premium | premium | premium | premium |
| 96523 | Irrigation of implanted venous access drug delivery device | premium | premium | premium | premium |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | premium | premium | premium | premium |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | premium | premium | premium | premium |
| 90653 | Influenza vaccine, inactivated | premium | premium | premium | premium |
| G0008 | Administration of influenza virus vaccine | premium | premium | premium | premium |
| 99204 | New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more | premium | premium | premium | premium |
| 36415 | Insertion of needle into vein for collection of blood sample | premium | premium | premium | premium |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | premium | premium | premium | premium |
These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.